Atrial Fibrillation - Pipeline Insight, 2024

This “Atrial Fibrillation - Pipeline Insight, 2024” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Atrial Fibrillation pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Atrial Fibrillation: Understanding

Atrial Fibrillation: Overview

Atrial fibrillation is the most common type of cardiac arrhythmia. It is due to abnormal electrical activity within the atria of the heart, causing them to fibrillate. It is characterized as a tachyarrhythmia, which means that the heart rate is often fast. This arrhythmia may be paroxysmal (less than seven days) or persistent (more than seven days). Due to its rhythm irregularity, blood flow through the heart becomes turbulent and has a high chance of forming a thrombus (blood clot), which can ultimately dislodge and cause a stroke. Atrial fibrillation is the leading cardiac cause of stroke. Risk factors for atrial fibrillation include advanced age, high blood pressure, underlying heart and lung disease, congenital heart disease, and increased alcohol consumption. Symptoms vary from asymptomatic to symptoms such as chest pain, palpitations, fast heart rate, shortness of breath, nausea, dizziness, diaphoresis (severe sweating), and generalized fatigue. Although atrial fibrillation may be a permanent disease, various treatments, and risk modifying strategies have been developed to help reduce the risk of stroke in patients that remain in atrial fibrillation. Treatments include anticoagulation, rate control medication, rhythm control medication, cardioversion, ablation, and other interventional cardiac procedures. Atrial fibrillation is the most commonly encountered cardiac rhythm disorder. The prevalence of atrial fibrillation has been increasing worldwide. It is known that the prevalence of atrial fibrillation generally increases with age. It has been estimated that the number of individuals with atrial fibrillation will double or triple by the year 2050. Although the worldwide prevalence of atrial fibrillation is approximately 1%, it is found in approximately 9% of individuals over the age of 75. At the age of 80, the lifetime risk of developing atrial fibrillation jumps to 22%. In addition, atrial fibrillation has more commonly been associated with males and is seen more often in whites as compared to blacks.

Atrial fibrillation (AFib) is diagnosed through various tests and examinations. Healthcare providers may discover AFib during routine checkups or when investigating other health issues. To diagnose AFib, a provider will conduct a physical examination, review medical history, and inquire about symptoms. Diagnostic tests include blood tests to check for underlying conditions, an electrocardiogram (ECG) to measure heart activity, Holter monitors or event recorders for continuous heart monitoring, and echocardiograms to visualize heart function. Exercise stress tests may also be used to assess heart response to physical activity. Early detection is crucial as AFib can lead to serious complications like stroke and heart failure. Treatment for atrial fibrillation (AFib) involves a range of options tailored to individual needs. Medications are commonly used to control heart rate, restore normal heart rhythm, and prevent blood clots that can lead to strokes. Anti-arrhythmic medicines like flecainide and beta blockers such as sotalol are used to restore normal heart rhythm, while blood thinners like warfarin or newer anticoagulants like dabigatran are prescribed to reduce the risk of stroke. Cardioversion, a procedure involving controlled electric shocks to the heart, may be recommended to restore a normal rhythm, especially if AFib symptoms are bothersome or during the first AFib episode. In cases where medications and cardioversion are not effective, procedures like catheter ablation or surgical maze procedures may be considered to manage AFib. Lifestyle changes such as quitting smoking, maintaining a healthy weight, controlling blood pressure, managing cholesterol levels, and reducing stress can also play a significant role in managing AFib. It's crucial to work closely with healthcare providers to determine the most suitable treatment plan based on factors like age, overall health, and type of AFib, symptoms, and underlying causes.

"Atrial Fibrillation- Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Atrial Fibrillation pipeline landscape is provided which includes the disease overview and Atrial Fibrillation treatment guidelines. The assessment part of the report embraces, in depth Atrial Fibrillation commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Atrial Fibrillation collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Atrial Fibrillation R&D. The therapies under development are focused on novel approaches to treat/improve Atrial Fibrillation.

Atrial Fibrillation Emerging Drugs Chapters

This segment of the Atrial Fibrillation report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Atrial Fibrillation Emerging Drugs

Milvexian: Bristol-Myers Squibb

Milvexian (BMS-986177) is an investigational, oral factor XIa (FXIa) inhibitor being studied for the prevention and treatment of major thrombotic conditions, including ischemic stroke, acute coronary syndrome, atrial fibrillation, atrial flutter, and venous thromboembolism. It is administered through oral routes as a suspension, tablets, and capsules. Milvexian acts by targeting FXIa, a cofactor that plays a crucial role in the coagulation cascade. The Librexia program, which is the most comprehensive FXIa clinical development program to date, is evaluating milvexian in three parallel clinical trials (Librexia STROKE, Librexia ACS, and Librexia AF). Currently, the drug is in Phase III stage of its clinical trial for the treatment of atrial fibrillation.

Etripamil: Milestone Pharmaceuticals

Etripamil is designed to be a rapid-response therapy for episodic cardiovascular conditions. The novel calcium channel blocker is self-administered via a nasal spray, which may shift the current treatment paradigm for many patients with PSVT from the emergency department to the at-home setting. The drug is in Phase III clinical studies for the treatment of paroxysmal supraventricular tachycardia and in Phase II clinical studies to treat atrial fibrillation.

AP31969: Acesion Pharma

AP31969 is a second-generation oral SK channel inhibitor being developed by Acesion Pharma for chronic oral maintenance treatment to prevent AF recurrence. The drug has demonstrated a low risk of proarrhythmia in pre-clinical studies, with no prolongations of the corrected QT interval in two in-vivo large animal models. AP31969 also has good oral pharmacokinetic properties and a low risk of causing drug-drug interactions. Currently, the drug is in Phase I stage of its clinical trial for the treatment of atrial fibrillation.

Atrial Fibrillation: Therapeutic Assessment

This segment of the report provides insights about the different Atrial Fibrillation drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Atrial Fibrillation

• There are approx. 12+ key companies which are developing the therapies for Atrial Fibrillation. The companies which have their Atrial Fibrillation drug candidates in the most advanced stage, i.e. Phase III include, Bristol-Myers Squibb.

Phases

DelveInsight’s report covers around 12+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Atrial Fibrillation pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Atrial Fibrillation: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Atrial Fibrillation therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Atrial Fibrillation drugs.

Atrial Fibrillation Report Insights

• Atrial Fibrillation Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Atrial Fibrillation Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Atrial Fibrillation drugs?
• How many Atrial Fibrillation drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Atrial Fibrillation?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Atrial Fibrillation therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Atrial Fibrillation and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Omeicos Therapeutics
• HUYABIO International
• Acesion Pharma
• Bristol-Myers Squibb
• Anthos Therapeutic
• Milestone Pharmaceuticals
• ARCA biopharma
• Thryv Therapeutics

Key Products

• OMT-28
• HBI-3000
• AP31969
• Milvexian
• Abelacimab
• Etripamil
• Bucindolol
• LQT-1268

This product will be delivered within 1-3 business days.